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Abstract
We present a case of Stevens Johnson syndrome in a child after carbamazepine
application and Stevens Johnson/TEN overlap syndrome in an adult after
amoxicillin application. On the basis of two reported cases we review the most
commonly associated drugs, the postulated pathogenesis, clinical manifestation
and management in these severe life-threatening diseases. We especially discuss
the controversial systemic corticosteroid therapy. Topical care is also discussed.
K Ke ey y   w wo or rd ds s: :   Stevens Johnson syndrome.
Introduction
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
are both acute life-threatening dermatoses characterized by extensive
epidermal sloughing at the dermoepidermal junction resulting from
keratinocyte apoptosis [1]. Both conditions are mostly elicited by drugs
and/or their metabolites and they form part of the spectrum of erythema
multiforme (EM). According to the classification proposed by Bastuji-Gari
et al., cutaneous lesions of Stevens Johnson syndrome are more extensive
than erythema multiforme, and epidermal necrolysis becomes a dominant
feature with the involvement of up to 10% of the body surface. Severe
mucous membrane lesions appear in patients with Stevens Johnson
syndrome,  and  also  in  oral,  conjunctival  and  genital  areas,  with
a propensity for scarring and bacterial superinfection [2]. Patients with
widespread macules or flat targets and 10-30% detachment are considered
to suffer from SJS/TEN overlap syndrome [3].
Case reports
C Ca as se e   n nu um mb be er r   1 1   ( (S SJ JS S/ /T TE EN N   o ov ve er rl la ap p   s sy yn nd dr ro om me e) )
The 54-year-old woman was referred to our department with acute
generalized skin eruptions and mucosal erosions after receiving amoxicillin
for acute bronchitis. Lesions appeared rapidly and simultaneously after 
2 doses of the antibiotic. Severe desquamation all over the body was
observed and Nikolsky’s sign was positive (Figure 1). Erythematous macular
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lesions showed rapid confluence. The patient showed
severe mucous membrane lesions of oral, conjunctival
(Figure 2) and genital areas. Eroded lesions on the lips
were covered with haemorrhagic crusts. She had
acute ocular findings such as purulent conjunctivitis
with severe eyelid oedema and pseudomembrane
formation. The general status was bad. Systemic
symptoms were: fever, sore throat, and dysphagia.
Our patient was also suffering from agoraphobia,
insulin-dependent diabetes and arterial hypertension,
making the management more difficult. The diagnosis
was performed on the basis of clinical features. The
main  laboratory  findings  were:  leukocytosis,
sedimentation rate 64/107, the presence of bacteria,
leucocytes  and  erythrocytes  in  urine  analysis,
significant hypoalbuminaemia and higher level of
transaminases. Our patient was treated in coopera-
tion  with  specialists  of  internal  disease,  an
ophthalmologist and a psychiatrist. The basis of
therapy was intravenous fluid replacement, steroid
intravenous therapy with dexamethasone, initially
8 mg three times a day, tapered gradually during 
12 days. We also administered ciprofloxacin because of
urinary tract infection. The patient required systematic
control of glucose level. Topical antimicrobial dressings
and ophthalmological care were also very important.
After therapy all symptoms and skin lesions resolved
progressively. The skin lesions healed without scarring
but with hyperpigmentation, during 3 weeks, and the
patient left our department in a good general state.
C Ca as se e   n nu um mb be er r   2 2   ( (S St te ev ve en ns s   J Jo oh hn ns so on n   s sy yn nd dr ro om me e) )
The  12-year-old  girl  was  admitted  to  our
department from the Paediatric Intensive Care Unit.
She developed multiple skin lesions, but also oral
mucosa involvement and severe conjunctival lesions
occurred after 2 weeks of starting carbamazepine
treatment for epilepsy. Her general state was severe
at the beginning of treatment, with fever, headache
and dysphagia. In dermatological examination,
multiple erythematous lesions with blisters and
large desquamation were observed (Figure 3). She
had  eroded  lesions  on  the  lips  covered  with
haemorrhagic crusts and severe oedema of eyelids
and lips (Figure 4). Changes in laboratory analysis
included high CRP level and hypoalbuminaemia. The
carbamazepine treatment was stopped immediately
and the drug was replaced with Depakine Chrono.
Our management was mainly supportive, with
attention to fluid balance, nutritional status and
pain relief. Initially, she was receiving hydrocortisone
intravenously during 9 days 3 ￗ 150 mg tapered
systematically  and  later  30 mg  of  prednisone
tapered during 3 weeks. Other treatment included
systemic antibiotic, antimicrobial dressings and
F Fi ig gu ur re e   1 1. .   Positive Nikolsky’s sign 
F Fi ig gu ur re e   2 2. .   Mucous membrane involvement in SJS with
typical erosions and haemorragic crusts on lips
F Fi ig gu ur re e   3 3. .   Erythematous macules with blisters typical
for erythema multiforme/SJS
F Fi ig gu ur re e   4 4. .   Mucous membrane lesions in SJS
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ophthalmological treatment. All lesions healed
rapidly within 2 weeks.
Discussion
Stevens Johnson syndrome (SJS) and SJS/TEN
overlap  syndrome  are  necrolytic  and  bullous
reactions to drugs constituting part of the erythema
multiforme  (EM)  disease  spectrum.  Results  of
a multinational study revealed that allopurinol is
the drug most commonly associated with SJS or
TEN [4]. Commonly associated drugs also include:
antibacterial sulfonamides, anticonvulsant agents,
non-steroidal anti-inflammatory drugs, amino-
penicillins and quinolones [5]. This syndrome was
reported  less  frequently  after  tetracyclines,
methotrexate and antiretroviral drugs such as
zidovudine and lamivudine [6, 7]. Among drugs
recently  introduced  to  the  market,  strong
associations were documented for nevirapine and
lamotrigine, and weaker for sertraline, pantoprazole
and tramadol. The use of such drugs as first line
therapies should be considered carefully, especially
when safer alternative treatments exist [8].
Several  mechanisms  of  pathogenesis  are
postulated. Some authors suggest that SJS and TEN
are the result of deficiency concerning mechanisms
involved in detoxification of reactive intermediary
metabolites. Others postulate the role of several
immunologically mediated mechanisms including
damage mediated through CD8+ cytotoxic T cells
causing  epidermal  necrosis  [2].  The  extensive
keratinocyte apoptosis is at least in part mediated
by the interaction of the fas receptor and fas ligand
[9]. A genetic predisposition and associations with
some HLA antigens have been postulated. Genetic
predisposition to SJS seems to be distinct from that
of TEN [10]. 
The diagnosis of SJS/TEN is made clinically and
the first step is to withdraw the offending drugs.
Clinical manifestation varies between patients,
depending on the degree of skin loss and extent of
mucosal involvement. As we observed, concomitant
diseases such as insulin-dependent diabetes tend
to worsen during SJS; they influence the general
state  and  make  treatment  more  difficult.  If
widespread cutaneous epidermal necrolysis occurs,
the patient develops an imbalance of fluid and
electrolyte  homeostasis.  Involvement  of  the
oesophagus may result in strictures. Rarely reported
symptoms are pneumothorax and mediastinal
emphysema.  Pneumonia  is  often  the  leading
symptom in severe cases. Hepatitis and myocardial
damage can be observed. Cardiac failure may result
from increased cutaneous blood flow, especially in
older individuals with prior cardiac disease [11].
In differential diagnosis, DRESS syndrome should
be considered. Drug rash with eosinophilia and
systemic symptoms (DRESS) is a multisystemic
disorder resulting from reaction to certain drugs,
especially anticonvulsants, but also sulfonamides,
minocycline, allopurinol and others. The diagnosis
of DRESS involves 3 criteria: drug-induced skin
eruption, eosinophilia > 1.5 ￗ 109/l or atypical
lymphocytes,  and  at  least  1  of  such  systemic
abnormalities  as  hepatitis,  nephropathy,  lung
disease, myocardial involvement, or enlarged lymph
nodes. Skin lesions could be oedematous and
convert to blisters. Nikolsky’s sign could be positive.
The  patient  often  has  fever  and  malaise  [12].
Maculopapular  exanthema  should  also  be
considered in differential diagnosis. It is one of the
most common cutaneous adverse drug reactions.
One of the most frequent responsible drugs is
amoxicillin, especially in patients with infectious
mononucleosis. The rash usually involves the whole
body but the face is often spared. These lesions do
not convert to blisters and the course is mild in
comparison to SJS and TEN. Some patients with an
extensive  maculopapular  drug  eruption  or
erythroderma may have extensive desquamation
which can be confused with TEN [13]. We should
think of Finkelstein’s disease in infants who develop
certain purpuric, oedematous targets in addition to
classic  target  lesions.  The  most  important
differential diagnosis, especially in children and
younger adults, is staphylococcal scalded skin
syndrome (SSSS). Patients suffer from widespread
skin erosions or display multiple vesicles. Nikolsky’s
sign is positive but these patients never develop
mucous membrane lesions [4].
Patients suffering from SJS and TEN need careful
and multidisciplinary therapeutic management.
Medical  therapy  for  SJS  and  TEN  remains
controversial, especially concerning the use of
systemic  corticosteroids.  These  drugs  are  the
mainstay in some units but other investigators
consider  systemic  corticosteroids  to  provoke
prolonged wound healing and increased risk of
infection,  hiding  early  signs  of  sepsis,  severe
gastrointestinal bleeding and increased mortality
[14,  15].  Thus  corticosteroids  have  not  been
recommended routinely. In contrast, a favourable
influence  of  high  doses  of  systemic  steroids
tapering over 7-10 days during the course of disease
was observed by several authors [16-18]. Others
only  advocated  their  use  in  SJS  as  the  skin
destruction is too extensive in TEN to be reversed
by the anti-inflammatory effects of steroids [19].
Nowadays, according to most authors, systemic
corticosteroids are of unproven benefit in the early
disease  stage  and  are  clearly  deleterious  in
advanced forms of TEN/SJS. 
Control  of  infection  is  a major  task  in  the
management of these patients. Empirical antibiotic
use is generally avoided and reserved for infection
confirmed by a positive culture [2]. The early use of
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broad-spectrum  antibiotics  immediately  after
admission may provoke the growth of multi-resistant
microbes and the risk of Candida sepsis [19].
Cyclosporine has also been proposed as a drug
with potential benefits in the management of TEN.
Cyclosporine is strongly immunosuppressive and
anti-apoptotic. Concerning the described cases,
patients received 3 mg/kg daily for two weeks and
then this dose was tapered off. Time to achieve 
re-epithelialization  was  about  12  days  [20].
Cyclophosphamide  is  also  proposed  by  some
authors in an initial dose of 300 mg per day [20].
Another  possible  method  of  treatment  is
intravenous immunoglobulin used in cases of SJS
and TEN as a substance significantly decreasing
mortality rates in patients. Intravenous immuno-
globulin blocks fas ligand binding to the fas receptor
and interferes with the downstream signalling
responsible for apoptosis . In the described cases,
disease progression was rapidly interrupted and all
patients survived. Patients were treated with doses
ranging  from  0.2  to  0.75  g/kg  per  day  of  i.v.
immunoglobulin over four consecutive days [21].
Some clinicians have included daily plasma-
pheresis  over  a period  of  3  days  into  their
treatment. It is well tolerated and aims at the
elimination  of  drugs,  drug  metabolites  and
inflammatory cytokines [19].
Topical therapy is essential to reduce loss of fluid
and electrolytes and to prevent infections [21]. We
use  mild  topical  antiseptic  solutions,  such  as
chlorhexidine  and  silver  nitrate.  If  biological
compounds  are  not  available,  synthetic  and
semisynthetic bandages should be applied. It is
important to keep the wounds wet to prevent
progression of necrosis. Changes of dressings have
to be performed under aseptic conditions once daily
and a microbial test for wound infection should be
performed at least three times per week from
various body parts [20]. There are several dressing
options available for treating TEN and SJS: porcine
xenografts, synthetic dressings, dressings with
occlusive silver nitrate gauze, and the traditional
Vaseline impregnated gauze [2]. Topical therapy of
mucous membrane includes repeated mouthwashes
with antiseptic compounds and application of local
anaesthetics, for example chlorhexidine rinses and
white petrolatum, to lips [20].
Eye care plays a crucial role in the management
of SJS/TEN patients, since ocular involvement may
lead  to  severe  complications  and  long-term
consequences ranging from visual impairment to
synechia formation and complete blindness. The
most common late complication is severe dry eyes
[23]. The severity of acute ocular complications does
not predict late complications. The diagnosis of TEN
does not imply a more severe ocular involvement
or increased frequency of late ocular complications
compared with SJS. Care should be taken even in
mild cases. Ophthalmologists have to see the
patient every day to check whether the eye is
lubricated or if there are any signs of infection.
Topical  antibiotics  should  not  be  empirically
administered unless there are clinical signs of
concomitant ocular infection [23].
All patients must be daily examined for an
imbalance  of  fluid,  protein  and  electrolyte
homeostasis. The control of red and white blood
cell  as  well  as  blood  coagulation  factors  and
fibrinolytic activity is also necessary [24]. Well
balanced  nutrition  is  essential  because  many
patients are unable to eat as a result of massive
pain caused by oral mucosa lesions [20].
We conclude that early diagnosis, supportive
care and careful monitoring for complications
comprise crucial management in SJS. 
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